Table 1. Baseline Demographic and Clinical Characteristics for Female African American and Hispanic Patients.
| Female African American | Hispanic | |||||
|---|---|---|---|---|---|---|
| PI (weighted n=1703) | INSTI (weighted n=1704) | |d|a | PI (weighted n=1846) | INSTI (weighted n=1865) | |d|a | |
| Age, mean (SD) | 47.2 (10.3) | 46.9 (11.3) | 2.6% | 43.3 (10.9) | 43.0 (13.3) | 2.4% |
| Female, n (%) | N/A | N/A | N/A | 475 (25.7) | 462 (24.8) | 2.2% |
| Race, n (%) | ||||||
| African American | N/A | N/A | N/A | 51 (2.8) | 101 (5.4) | 13.6% |
| Asian | N/A | N/A | N/A | 0 (0.0) | 6 (0.4) | 8.3% |
| Caucasian | N/A | N/A | N/A | 1126 (61.0) | 959 (51.4) | 19.5% |
| Other/unknown | N/A | N/A | N/A | 669 (36.2) | 799 (42.8) | 13.5% |
| Insurance plan type, n (%) | ||||||
| Commercial | 167 (9.8) | 299 (17.6) | 22.8% | 291 (15.8) | 469 (25.2) | 23.5% |
| Medicaid | 371 (21.8) | 229 (13.4) | 22.0% | 81 (4.4) | 169 (9.0) | 18.6% |
| Medicare | 164 (9.7) | 69 (4.0) | 22.4% | 68 (3.7) | 85 (4.6) | 4.5% |
| Otherb | 144 (8.5) | 176 (10.4) | 6.5% | 439 (23.8) | 360 (19.3) | 18.1% |
| Missing | 858 (50.3) | 930 (54.6) | 8.6% | 967 (52.4) | 783 (42.0) | 20.9% |
| Baseline weight, mean (SD) | 83.2 (22.6) | 82.8 (25.4) | 2.0% | 77.2 (20.2) | 78.5 (18.1) | 7.1% |
| Baseline BMI, mean (SD) | 30.6 (8.3) | 30.8 (9.2) | 2.0% | 27.2 (6.1) | 27.4 (6.1) | 2.7% |
| Baseline BMI category, n (%) | ||||||
| Underweight (BMI<18.5) | 49 (2.9) | 62 (3.7) | 4.3% | 107 (5.8) | 54 (2.9) | 14.4% |
| Normal (BMI 18.5-24.9) | 319 (18.7) | 414 (24.3) | 13.6% | 526 (28.5) | 634 (34.0) | 11.9% |
| Overweight (BMI 25.0-29.9) | 464 (27.3) | 389 (22.8) | 10.2% | 681 (36.9) | 608 (32.6) | 8.9% |
| Obese (BMI ≥30) | 806 (47.3) | 776 (45.6) | 3.5% | 437 (23.7) | 502 (26.9) | 7.4% |
| Missing | 65 (3.8) | 63 (3.7) | 0.6% | 95 (5.1) | 68 (3.6) | 7.3% |
| Baseline comorbidities | ||||||
| QCI score, mean (SD) | 3.2 (2.5) | 3.2 (2.3) | 1.0% | 3.1 (2.1) | 3.1 (2.2) | 1.2% |
| No. of CVD risk conditions, mean (SD) | 0.8 (1.0) | 0.8 (1.0) | 0.6% | 0.6 (0.9) | 0.5 (0.9) | 3.9% |
| Individual conditions, n (%) | ||||||
| T2DM | 277 (16.2) | 263 (15.4) | 2.2% | 239 (12.9) | 232 (12.5) | 1.5% |
| Hypertension | 522 (30.6) | 620 (36.4) | 12.2% | 317 (17.2) | 310 (16.6) | 1.4% |
| Hyperlipidemia | 247 (14.5) | 244 (14.3) | 0.5% | 337 (18.3) | 307 (16.5) | 4.7% |
| AIDS | 1,074 (63.0) | 1,127 (66.2) | 6.5% | 1,222 (66.2) | 1,283 (68.8) | 5.6% |
| No. of drugs used at baseline, mean (SD)c | 0.6 (1.0) | 0.7 (1.2) | 2.5% | 0.4 (0.7) | 0.4 (0.9) | 2.8% |
Abbreviations: BMI, body mass index; CVD, cardiovascular diseases; INSTI, integrase inhibitors; PI, protease inhibitors; QCI, Quan Charlson Comorbidity Index; T2DM, type 2 diabetes mellitus.
a Standard difference, with |d| ≥10% being considered as significant.
b Includes Multiple, Uninsured, Unknown, or Other.